Share on StockTwits

CombiMatrix (NASDAQ:CBMX) CEO Mark D. Mcdonough bought 12,000 shares of the stock on the open market in a transaction dated Wednesday, August 27th. The shares were purchased at an average cost of $2.02 per share, with a total value of $24,240.00. Following the completion of the acquisition, the chief executive officer now directly owns 13,500 shares of the company’s stock, valued at approximately $27,270. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Separately, analysts at Zacks reiterated an “outperform” rating on shares of CombiMatrix in a research note on Friday, August 8th. They now have a $3.50 price target on the stock.

CombiMatrix (NASDAQ:CBMX) traded down 3.90% on Thursday, hitting $1.97. The stock had a trading volume of 166,493 shares. CombiMatrix has a 52-week low of $1.91 and a 52-week high of $4.44. The stock’s 50-day moving average is $2.16 and its 200-day moving average is $2.49. The company’s market cap is $21.8 million.

CombiMatrix Corporation is a molecular diagnostics company. The Company operates in the field of genetic analysis and molecular diagnostics through its wholly owned subsidiary, CombiMatrix Molecular Diagnostics, Inc located in Irvine, California.

Receive News & Ratings for CombiMatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CombiMatrix and related companies with Analyst Ratings Network's FREE daily email newsletter.